Literature DB >> 19858427

Adverse events in randomized trials: neglected, restricted, distorted, and silenced.

John P A Ioannidis.   

Abstract

Mesh：

Year:  2009        PMID： 19858427     DOI： 10.1001/archinternmed.2009.313

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  63 in total

Review 1.  Depression in patients with heart disease: the case for more trials.

Authors:  Stanley S Liu; Roy C Ziegelstein
Journal:  Future Cardiol       Date:  2010-07

2.  Physicians' perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey.

Authors:  Enrique Ginzburg; Franck Dujardin
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

3.  Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.

Authors:  Daniel M Hartung; Deborah A Zarin; Jeanne-Marie Guise; Marian McDonagh; Robin Paynter; Mark Helfand
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

4.  Insufficient evaluation of adverse events is not a proof of safety.

Authors:  L G Hemkens; U Grouven; R Bender; P T Sawicki
Journal:  Diabetologia       Date:  2010-01-23       Impact factor: 10.122

5.  Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?

Authors:  Pascale Olivier; Anne Gimbert; Anne-Laurène Colin; Francesco Salvo; Madlyne Becker; Valérie Marty; Jean-Louis Montastruc; Nadine Petitpain
Journal:  Br J Clin Pharmacol       Date:  2016-07-13       Impact factor: 4.335

Review 6.  Benefit and harms of new anti-cancer drugs.

Authors:  Francisco E Vera-Badillo; Mustafa Al-Mubarak; Arnoud J Templeton; Eitan Amir
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

7.  Has evidence-based medicine left quackery behind?

Authors:  Florian Naudet; Bruno Falissard; Rémy Boussageon; David Healy
Journal:  Intern Emerg Med       Date:  2015-04-01       Impact factor: 3.397

8.  The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis.

Authors:  M Solmi; C U Correll; A F Carvalho; J P A Ioannidis
Journal:  Epidemiol Psychiatr Sci       Date:  2018-07-16       Impact factor: 6.892

Review 9.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Authors:  Gianluca Trifirò; Rosa Gini; Francesco Barone-Adesi; Ettore Beghi; Anna Cantarutti; Annalisa Capuano; Carla Carnovale; Antonio Clavenna; Mirosa Dellagiovanna; Carmen Ferrajolo; Matteo Franchi; Ylenia Ingrasciotta; Ursula Kirchmayer; Francesco Lapi; Roberto Leone; Olivia Leoni; Ersilia Lucenteforte; Ugo Moretti; Alessandro Mugelli; Luigi Naldi; Elisabetta Poluzzi; Concita Rafaniello; Federico Rea; Janet Sultana; Mauro Tettamanti; Giuseppe Traversa; Alfredo Vannacci; Lorenzo Mantovani; Giovanni Corrao
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

Review 10.  Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network.

Authors:  Iveta Simera; David Moher; Allison Hirst; John Hoey; Kenneth F Schulz; Douglas G Altman
Journal:  BMC Med       Date:  2010-04-26       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.